The Indian Pharmacopoeia Commission (IPC), in collaboration with Council of Scientific and Industrial Research (CSIR), organized a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 at CSIR-Indian Institute of Integrative Medicine (CSIR-IIIM), Jammu on 17th April 2026.
The conclave brought together experts from regulatory bodies, academia, and the pharmaceutical sector to deliberate on key developments in pharmacopoeial standards and their role in ensuring the quality, safety, and efficacy of medicines.
The inaugural session featured addresses by senior officials and experts, highlighting the importance of strengthening drug standards in line with evolving scientific and regulatory requirements. The discussions emphasized the role of the Indian Pharmacopoeia as a critical tool in maintaining uniform standards for pharmaceuticals across the country.
The technical sessions focused on recent updates in Indian Pharmacopoeia (IP) 2026, including development and revision of monographs, strengthening of impurity standards, and adoption of modern analytical approaches. Deliberations also covered regulatory perspectives, standardization of phytopharmaceuticals, and enhancement of microbiological and blood-related standards, reflecting a comprehensive approach towards improving pharmaceutical quality systems.
The interactive session provided a platform for stakeholders to exchange views on implementation aspects of IP 2026, industry preparedness, and the need for continued alignment with global standards. Participants highlighted the importance of collaboration between regulators, industry, and scientific institutions to ensure effective adoption of updated standards.
The conclave reaffirmed the commitment of the Indian Pharmacopoeia Commission (IPC) to continuously upgrade pharmacopoeial standards through scientific advancements and stakeholder engagement, thereby contributing to the strengthening of public health safeguards in the country.
